Fractyl Health, Inc. (GUTS) Stock Score, Valuation & Financial Research

Fractyl Health, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GUTS

Fractyl Health, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 4.57. These figures are a research snapshot, not a buy or sell recommendation.

What Fractyl Health, Inc. does

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Fractyl Health is a clinical-stage metabolic therapeutics company that does not currently generate commercial revenue from product sales. Its business model focuses on the research and development of novel procedural and gene therapy candidates for obesity and type 2 diabetes, relying on capital raises and equity financing to fund its ongoing clinical trials and operations.

Products and services

  • The company's primary product candidate is Revita, an endoscopic procedure designed to remodel the duodenal lining to improve metabolic health. It also maintains the Rejuva platform, which is in preclinical development for AAV-based gene therapies targeting obesity and type 2 diabetes.

Brands and product families

  • Revita — Lead product candidate for duodenal mucosal resurfacing. Source
  • Rejuva — Preclinical platform for AAV-based gene therapies. Source

Suppliers, materials and equipment

  • Contract Research Organizations and Contract Manufacturing Organizations — The company relies on third-party contract research organizations and contract manufacturing organizations for clinical trial management and the production of clinical trial materials. Specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Pharmaceutical and Biotechnology Companies — The company faces competition from entities developing GLP-1 receptor agonists and other pharmacological treatments for obesity and type 2 diabetes. Source

Business strengths to evaluate

  • Proprietary Revita and Rejuva technology platforms Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GUTS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.57
Market capitalization:
60.42M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -105.65M
Free cash flow:
USD -90.89M
Cash:
USD 47.14M
Total debt:
USD 60.74M
EPS:
USD -1.10

What stands out

  • Free cash flow is USD -90.89M, negative for the stored period.
  • The balance sheet shows USD 47.14M of cash versus USD 60.74M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 13.6M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GUTS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can GUTS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does GUTS's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for GUTS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of GUTS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research GUTS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.